SynthesisClinical and experimental medicine2026
Multiple Myeloma in Children and Young Adults: A Systematic Literature Review.
Synthesis in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is extremely rare in pediatric and young adult populations, and its clinical characteristics, therapeutic strategies, and outcomes remain poorly defined. This systematic review consolidates all published cases of MM in patients aged ≤ 25 years, aiming to define epidemiology, presentation, treatment, and theraupeutic outcomes. A systematic literature search was conducted in PubMed up to December 31, 2024, to identify case reports and series of MM in patients ≤ 25 years. Articles lacking patient-specific data, definitive diagnostic criteria, or full English text were excluded. Data on demographics, clinical features, cytogenetics, treatment regimens, and outcomes were extracted. Forty-two patients were included from 33 publications, with a median age of 17 years (range 8-25). Male predominance was noted (M: F = 1.47:1). Common presenting features included bone pain (42.9%) and neurological symptoms (21.4%). IgG myeloma was most frequent, followed by IgA, light-chain only and IgD subtypes. Plasmacytomas were observed in 61.9%, including 30.8% with extramedullary and 57.7% with paramedullary involvement. Cytogenetic abnormalities were detected in 75% of evaluable patients. First-line therapy varied by era, with regimens including conventional chemotherapy, novel agents, and hematopoietic stem cell transplantation (HSCT). Among the 16 patients with evaluable treatment response, the overall response rate to first-line therapy was 75%. Hematopoietic stem cell transplantation (HSCT) was performed in 10 patients and was associated with deeper treatment responses. Contemporary therapeutic regimens were generally well tolerated, and no therapy-related mortality was reported. MM in patients aged ≤ 25 years is a rare clinical entity that may present with distinctive features, including a high frequency of plasmacytomas and extramedullary disease. Modern treatment strategies incorporating novel agents and HSCT appear feasible and effective in this population. Further collaborative studies are required to better define the biological characteristics and optimal management of MM in very young patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.